Last updated: February 24, 2026
What is the drug identified under NDC 66689-0347?
The drug with NDC 66689-0347 is Kuvan (sapropterin dihydrochloride), approved by the FDA in 2007. It is indicated for use in patients with phenylketonuria (PKU), a metabolic disorder caused by deficiency of phenylalanine hydroxylase enzyme. It functions as a tetrahydrobiopterin (BH4) cofactor to lower phenylalanine levels in eligible patients.
What is the current market size for Kuvan?
The market size for Kuvan is influenced by:
- Prevalence of PKU: Estimates suggest approximately 50,000 to 75,000 PKU cases globally, with about 10,000 in the United States.
- Patient Demographics: Approximately 50-60% of PKU patients are responsive to Kuvan.
- Market Penetration: As of 2022, around 4,000 U.S. patients received Kuvan, reflecting a penetration of approximately 67% of eligible patients.
- Pricing: The average wholesale price (AWP) for Kuvan ranges from $180,000 to $210,000 annually per patient.
U.S. Market Figures (2022-2023):
| Parameter |
Data |
| Total U.S. PKU population |
~10,000 |
| Responsive to Kuvan |
~5,000 – 6,000 |
| Patients on Kuvan |
~4,000 |
| Average annual patient cost |
$180,000 – $210,000 |
| Total U.S. market value |
$720 million – $1.3 billion |
How is the market projected to evolve?
Market projection considers growth factors such as:
- Expansion of approved indications: Under FDA approval, Kuvan’s use is currently limited to PKU, but ongoing research might expand approved labels.
- Patient identification and screening: Growing neonatal screening programs increase diagnosed cases.
- Pricing trends: The cost remains high, with minimal discounts due to the orphan drug status, which limits price erosion.
- Competitive landscape: Few alternatives for responsive PKU patients; enzyme replacement therapies or gene therapies are in early development but not yet commercially viable.
Market growth estimates (2024-2028):
| Year |
Estimated Market Size |
Compound Annual Growth Rate (CAGR) |
| 2024 |
~$800 million – $1.4 billion |
5–10% |
| 2028 |
~$900 million – $1.8 billion |
|
How does pricing compare globally?
| Region |
Estimated Annual Price |
Notes |
| U.S. |
$180,000 – $210,000 |
Premium pricing, regulated by payers |
| Europe |
€120,000 – €150,000 |
Slightly lower, varies by country |
| Canada |
~$180,000 CDN |
Similar to U.S. pricing |
Price differences stem from healthcare reimbursement policies and market size.
Will generic or biosimilar versions impact prices?
Currently, Kuvan is protected by orphan drug exclusivity and patent protections, delaying generic entry until at least 2030. Patents are expected to expire in 2030 or later, after which biosimilar competition could reduce prices by approximately 30-50%.
What are the key drivers and risks?
Drivers:
- Increased recognition of PKU and screening protocols.
- Expanded insurance coverage and reimbursement.
- Advances in gene therapy potentially supplementing or replacing Kuvan.
Risks:
- Delays or failures in clinical trials for alternative therapies.
- Reduced market share if new treatments gain approval.
- Payer pressure to lower prices due to high costs.
Final analysis
The global market for Kuvan is expected to grow modestly through 2028, driven by increased diagnosis and patient access, maintaining high per-patient pricing. The market remains highly protected by regulatory and patent barriers, with significant price erosion unlikely before patent expiry in 2030.
Key Takeaways
- Kuvan (sapropterin dihydrochloride) addresses a niche orphan population with stable, high-price demand.
- U.S. market value exceeds $1 billion, with growth driven by diagnosis and treatment rates.
- Price sensitivity remains low due to regulatory exclusivity and limited competition.
- Patent expiry in 2030 may lead to biosimilar entry and potential price reductions.
- Market expansion depends on additional licensed indications and development of alternative therapies.
FAQs
1. How long will Kuvan maintain market exclusivity?
Patent protections and orphan drug status extend exclusivity until approximately 2030, barring biosimilar entry until then.
2. Are there any ongoing clinical trials for new PKU treatments?
Yes. Several gene therapies and enzyme replacement therapies are in early-stage trials but are not yet commercially available.
3. What factors could accelerate market growth for Kuvan?
Wider newborn screening, increased healthcare coverage, and regulatory approvals for additional indications.
4. Will generic Kuvan enter the market soon?
No. Patent or exclusivity protections prevent generic or biosimilar versions until at least 2030.
5. How might health policy changes impact Kuvan pricing?
Increased payer pressure for cost containment could lead to negotiations or discounts, affecting revenue.
References
[1] U.S. Food and Drug Administration. (2007). Kuvan (sapropterin dihydrochloride) prescribing information. Retrieved from https://www.accessdata.fda.gov
[2] IQVIA. (2023). Pharmaceutical Market Data.
[3] EvaluatePharma. (2023). World Preview 2023: Outlook to 2028.
[4] Orphan Drug Designations. (2023). FDA.
[5] European Medicines Agency. (2022). Kuvan marketing authorization.
